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Abstract
Background: Next Generation Sequencing (NGS) has become a valuable tool for molecular landscape characterization
of cancer genomes, leading to a better understanding of tumor onset and progression, and opening new avenues in
translational oncology. Formalin-fixed paraffin-embedded (FFPE) tissue is the method of choice for storage of clinical
samples, however low quality of FFPE genomic DNA (gDNA) can limit its use for downstream applications.
Methods: To investigate the FFPE specimen suitability for NGS analysis and to establish the performance of two
solution-based exome capture technologies, we compared the whole-exome sequencing (WES) data of gDNA
extracted from 5 fresh frozen (FF) and 5 matched FFPE lung adenocarcinoma tissues using: SeqCap EZ Human Exome
v.3.0 (Roche NimbleGen) and SureSelect XT Human All Exon v.5 (Agilent Technologies).
Results: Sequencing metrics on Illumina HiSeq were optimal for both exome systems and comparable among FFPE
and FF samples, with a slight increase of PCR duplicates in FFPE, mainly in Roche NimbleGen libraries. Comparison of
single nucleotide variants (SNVs) between FFPE-FF pairs reached overlapping values >90 % in both systems. Both WES
showed high concordance with target re-sequencing data by Ion PGM™ in 22 lung-cancer genes, regardless the
source of samples. Exon coverage of 623 cancer-related genes revealed high coverage efficiency of both kits,
proposing WES as a valid alternative to target re-sequencing.
Conclusions: High-quality and reliable data can be successfully obtained from WES of FFPE samples starting from a
relatively low amount of input gDNA, suggesting the inclusion of NGS-based tests into clinical contest. In conclusion,
our analysis suggests that the WES approach could be extended to a translational research context as well as to the
clinic (e.g. to study rare malignancies), where the simultaneous analysis of the whole coding region of the genome
may help in the detection of cancer-linked variants.
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Background
The advent of Next Generation Sequencing (NGS)
technology has revolutionized the knowledge of cancer
genomics becoming a valuable tool to characterize the
molecular landscape of cancer genomes in different
tumor types, including lung cancer [1–3]. NGS allows
to comprehensively identifying genetic variants associated
with individual cancer leading to a better understanding
of tumor onset and progression, opening new avenues in
the field of translational oncology [4–6].
Whole Exome Sequencing (WES), which targets a
large fraction of the protein coding region of the gen-
ome, is a widely used sequencing strategy. Indeed, it is a
cost-effective approach compared to the prohibitively
expensive whole genome sequencing and a valid alterna-
tive to gene panels [7–10]. However, WES is still rela-
tively expensive and it requires bioinformatic expertise
for data analysis; moreover, one of the major challenges
is represented by the quality and integrity of nucleic acid
extracted from available tumor tissues. The best source
of samples is fresh frozen (FF) sections, which results in
high quality DNA, although handling and storage often
limit the possibility to perform molecular analyses in-
cluding NGS. To date, formalin-fixed paraffin-embedded
(FFPE) preservation is the method of choice for the
archival storage of clinical samples in pathology archives
worldwide. Although the FFPE tumor tissue might be an
excellent resource for retrospective and prospective mo-
lecular genetic investigations, the low quality of resulting
DNA remains one of the major challenges. The difficulty
of extraction due to paraffin and protein-DNA inter-
actions, together with the adverse effect of formalin
fixatives, could result in chemical modification and
fragmentation of FFPE-derived DNA, limiting its use
for downstream applications [11–13]. In 2009, Schweiger
and colleagues for the first time successfully demonstrated
the possibility to obtain copy-number alterations and mu-
tation data using long-term storage FFPE samples without
any significant drawback when compared to matched FF
samples [14].
During the five past years, noteworthy efforts have
been made to establish the performance of different
exome capture systems and help define the most ap-
propriate capture system for each specific application
[15–21]. In addition, several groups evaluated the
FFPE-derived gDNA suitability in WES applications
[22–28] (Table 1). At present only two systematic
comparisons of different exome capture technologies
performance on FF and matched FFPE tissues have
been published [27, 28], however the comparison ana-
lyses were carried out on different sets of samples,
providing unclear results (Table 1).
Currently, the most used exome enrichment platforms
are characterized by the solution-based capture technol-
ogy and Roche NimbleGen and Agilent SureSelect are
two out of the four major commercially available plat-
forms [17, 21].
Here we present a comprehensive comparison of the
Roche NimbleGen SeqCap EZ Exome (v.3.0; 64 Mb) and
Agilent SureSelect XT (v.5; 50 Mb) (Table 2), on gen-
omic DNA (gDNA) extracted from FF and matched
FFPE tissue belonging to five lung adenocarcinoma
(ADC) patients.
A gDNA integrity quality control step was also included
to determine the suitability of FFPE tumor specimens for
WES analysis on Illumina HiSeq platform. Furthermore,
we compared WES data with PCR-based target re-
sequencing, evaluating the variant calling concordance of
90 amplicons within 22 lung cancer-related genes in-
cluded in the Ion AmpliSeq Colon and Lung Cancer Panel
v.1 (Thermo Fisher Scientific). Finally, we also assessed
the uniformity of coverage reached by the two exome en-
richment platforms in 623 cancer-related genes.
Methods
Clinical samples
Tissue samples were obtained from five patients diag-
nosed with histologically confirmed lung ADC who
underwent surgery (2 IB, 2 IIB and 1 patient IV stage of
disease). For each patient, FF and matched FFPE sam-
ples were collected from the Biological Resource Center
(CRB) and from diagnostic archive of IRCCS A.O.U.
San Martino – IST (Genova, Italy), respectively. Each
tumor sample was evaluated by pathologist prior to
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analysis and all specimens reported at least 50 % of
tumor cells content.
DNA extraction and quality control
gDNA from FF and matched FFPE tissues was extracted
by QIAamp® DNA Mini Kit and GeneRead DNA FFPE
Kit (Qiagen, Hilden, Germany), respectively. Quantity
and purity of gDNA were assessed by Qubit® 2.0
Fluorometer (Invitrogen, Carlsbad, CA, USA) and Nano-
Drop ND-1000 (Thermo Scientific, Wilmington, DE,
USA). Fragmentation status was evaluated by the Agilent
2200 TapeStation system using the Genomic DNA
ScreenTape assay (Agilent Technologies, Santa Clara,
CA, USA) able to produce a DNA Integrity Number
(DIN). An additional quality control (QC) step to assess
FFPE DNA integrity was performed using a multiplex
Polymerase Chain Reaction (PCR) approach [29]. Briefly,
30 ng of gDNA were amplified using three different-size
set of primers of Glyceraldehyde-3-Phosphate Dehydro-
genase (GAPDH) gene (200-300-400 base pair), and the
concentration of PCR products was determined by Agilent
2100 Bioanalyzer instrument (Agilent Technologies). Then,
to estimate FFPE gDNA fragmentation, we evaluated an
Average Yield Ratio (AYR) value, calculated by yield ratio
of each amplicon compared with a reference DNA
(Promega Madison, WI, USA).
WES library preparation and hybridization capture
A total of 300 ng of each gDNA sample based on
Qubit quantification were mechanically fragmented on
a E220 focused ultrasonicator Covaris (Covaris,
Woburn, MA, USA). Two hundred ng of sheared
gDNA were used to perform end repair, A-tailing and
adapter ligation with either Agilent SureSelect XT
(Agilent Technologies) or KAPA library preparation
kits (Kapa Biosystems Inc. Wilmington, MA, USA),
following the manufacturer instructions. Subsequently,
the libraries were captured using either Agilent
SureSelect Human All Exon v.5 (Agilent Technolo-
gies) or SeqCap EZ Human Exome Library v.3.0
Roche NimbleGen (Roche, Basel, Switzerland) probes
respectively, and finally amplified.
Illumina sequencing
After QC and quantification by Agilent 2100 Bioanalyzer
(Agilent Technologies) and Qubit® 2.0 Fluorometer
(Invitrogen), the libraries were sequenced on an Illumina
HiSeq 2500 platform (Illumina Inc, San Diego, CA,
USA) High Output mode, 2×100 cycles, with TruSeq
SBS v3 chemistry. For each library preparation type, 10
samples were loaded in a single lane of a flow-cell v3.
WES data analysis and statistical analysis
After sequencing, basecall files conversion and demulti-
plexing were performed with bcl2fastq software (Illumina).
The resulting fastq data were aligned to the human
reference genome (hg19) by Burrows-Wheeler Aligner
Maximal Exact Match (BWA-MEM) aligner [30]. We
assessed duplicated reads with Picard MarkDuplicates;
Picard HsMetrics [31] and Samtools [32] were used
Table 1 Overview of the most relevant WES comparison studies between FF and matched FFPE tissue samples
Study Number/Sample types Tissue type Exome capture kit
Holley et al. [22] 1 matched FF/FFPE pancreatic ductal adenocarcinoma Agilent SureSelect All Exon Plus
Van Allen et al. [23] 11 matched FF/FFPE lung adenocarcinoma + lung normal tissue Agilent SureSelect Human All Exon v.2
Hedegaard et al. [24] 19 matched FF/FFPE colorectal carcinoma + 13 matching normal
FF colon samples
Illumina TruSeq Exome Enrichment
Munchel et al. [25] 13 matched FF/FFPE 9 ovarian carcinomas, 2 breast tumor/normal
pairs, 2 colon tumor/normal pairs
Illumina TruSeq Exome Enrichment
Astolfi et al. [26] 4 matched FF/FFPE gastrointestinal stromal tumors + normal
samples (peripheral blood)
Illumina Nextera Rapid Capture Exome Enrichment
De Paoli-Iseppi et al. [27] 10 matched FF/FFPE melanoma Illumina TruSeq Exome (10 FF)
Illumina Nextera Rapid Capture Expanded Exome
(7 FFPE)
Roche NimbleGen SeqCap EZ Exome +UTR (4 FFPE)
Oh et al. [28] 4 matched FF/FFPE cancer type not defined + matched blood
or normal frozen sample
NimbleGen exome 2.1 M array (pair 1 and 4);
Agilent SureSelect All Human exon v.5 (pair 2 and 3).
Table 2 Comparison between Agilent SureSelect XT v.5 and





Probe type biotinylated cRNA biotinylated DNA
Probe length range (bp) 114-126 55-105




Total target length (Mb) 50 64
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to determine WES metrics. Reads realignment and
base recalibration were performed with the Genome
Analysis Toolkit (GATK) tools InDelRealigner and
BaseRecalibrator. Recalibrated Binary Alignment/Map
(BAM) files were used to perform variant calling with
the GATK-UnifiedGenotyper [33]. Two tails paired t and
ANOVA tests were performed by Microsoft Excel.
Selection of genes implicated in cancer
In order to select the most relevant cancer-related genes,
we focused on 5 different companies releasing commer-
cial re-sequencing panels. The selected 21 panels are the
following: Ion AmpliSeq™ Cancer Hotspot Panel v.2, Ion
AmpliSeq™ Colon and Lung Research Panel v.2, Ion
AmpliSeq™ Comprehensive Cancer Panel, Ion AmpliSeq™
Cancer Panel Primer Pool (Thermo Fisher Scientific);
TruSeq™ Amplicon Cancer Panel, TruSight™ Tumor Panel
(llumina Inc); Human Breast Cancer Panel, Human Colo-
rectal Cancer Panel, Human Liver Cancer Panel, Human
Lung Cancer Panel, Human Ovarian Cancer Panel,
Human Prostate Cancer Panel, Human Gastric Cancer
Panel, Human Cancer Predisposition Panel, Human Clin-
ically Relevant Tumor Panel, Human Tumor Actionable
Mutations Panel, Human Comprehensive Cancer Panel
(Qiagen), Somatic 1 MASTR v.2, Somatic 2 MASTR Plus
(Multiplicom, Niel, Belgium); Clear Seq Comprehensive
Cancer and Clear Seq Cancer (Agilent Technologies).
Coverage analysis of cancer genes
A total of 623 cancer-related genes was used to analyze
the coverage performance of WES enrichment systems
by the DiagnoseTargets tool from GATK. We set the
tool parameters in order to identify a ‘critical’ exon inter-
val in a single library when the average depth of cover-
age was less than 10× for at least 20 % of the exon
interval length. Finally, for each kit, all the intervals with
insufficient median depth across all FF and FFPE librar-
ies were considered ‘critical’.
The region coordinates (RefSeq coding exons) were
downloaded from UCSC Table Browser [34]. BEDTools
[35] was used to collapse coordinates to unique locations
in order to avoid overlap.
Target resequencing for WES validation
For targeted NGS analysis, the libraries were constructed
using the Ion AmpliSeq Colon and Lung Cancer Panel
v.1 (Thermo Fisher Scientific) which amplifies 90 ampli-
cons in hotspot regions of 22 Colon and Lung cancer-
related genes (AKT1, ALK, BRAF, CTNNB1, DDR2,
EGFR, ERBB2, ERBB4, FBXW7, FGFR1, FGFR2, FGFR3,
KRAS, MAP2K1, MET, NOTCH1, NRAS, PIK3CA,
PTEN, SMAD4, STK11, and TP53). gDNA extracted
from FFPE and FF samples (20 ng and 10 ng, respect-
ively) were amplified using the Ion AmpliSeq™ Library
Kit 2.0 (Thermo Fisher Scientific) according to the man-
ufacturer's instructions. After libraries quantification and
QC, performed by the 2200 TapeStation Instrument
(High Sensitivity Assay) and Qubit® 2.0 Fluorometer,
each library was diluted to 100pM, amplified through
emulsion PCR using the OneTouch™ Instrument
(Thermo Fisher Scientific) and enriched by the One-
Touch™ ES Instrument (Thermo Fisher Scientific) using
the Ion PGM Template OT2 200 KIT following manu-
facturer’s instructions. The targeted resequencing was
carried out on the Ion Personal Genome Machine
(PGM) sequencer (Ion Torrent™) using the Ion PGM
200 Sequencing Kit (Thermo Fisher Scientific) loading
barcoded libraries into 316v.2 chip. Sequencing was per-
formed using 500 flow runs generating approximately
200 bp reads. The PGM sequencing data analysis was
performed by the Ion Torrent Software Suite v.4.2
(Thermo Fisher Scientific) using the plugin Variant
Caller (VC) v.4.2-r88446. The called variants were anno-
tated by the Ion Reporter software v.4.2 and verified
using the Integrative Genomics Viewer (IGV) software.
Results
Quality control
gDNA was extracted from 5 FF and matched FFPE sam-
ples. A QC step was performed for each sample (Add-
itional file 1: Figure S1). FFPE gDNA fragmentation status
was evaluated using a multiplex PCR and an automated
gel-based electrophoresis system (2200 TapeStation In-
strument; Agilent Technologies) reporting variable deg-
radation status: the multiplex PCR revealed an AYR
ranging from 0.5–0.7, whereas the TapeStation reported a
DIN which ranged from 3.5–4.3. The AYR values highly
correlated with DIN data, although the two systems re-
ported different scales of measurement.
WES standard metrics comparison
WES was performed on all samples (5 FF and matching
FFPE), comparing two commercially available exome
capture systems: Roche NimbleGen SeqCap EZ Human
Exome Library v.3.0 (64 Mb) and Agilent SureSelect Hu-
man All Exon v.5 (50 Mb). The standard WES metrics,
computed for each library, are summarized in Additional
file 2: Table S1. No major differences were found be-
tween FF and FFPE libraries, and both exome capture
systems showed a similar sequencing performance
(Fig. 1). The percentage of reads mapping to the refer-
ence genome was higher than 99 % for both sample
types, irrespective of the kit used (Fig. 1a, Additional file
2: Table S1). Also the mean percentage of properly
paired reads was comparable, showing a value of 98.9 %
(range 98.3-99.1) and 97.4 % (range 95.3-98.1) in FF
and FFPE Agilent libraries respectively, and 99.1 %
(range 98.7-99.3) and 98.5 % (range 97.6-98.9) in FF




Fig. 1 (See legend on next page.)
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and FFPE Roche NimbleGen libraries respectively
(Fig. 1a, Additional file 2: Table S1). A slightly higher
percentage of duplicated reads was obtained in FFPE
compared with FF libraries for both exome capture
kits. However, overall Roche NimbleGen technology
achieved a higher level of duplicated reads (FF mean =
3.3 %; FFPE mean = 11.5 %) as compared to Agilent Sure-
Select kit (FF mean = 1.8 %; FFPE mean = 3.6 %) (Fig. 1a,
Additional file 2: Table S1). The percentage of duplicated
reads was higher in FFPE compared with FF libraries for
both exome capture kits (p = 0.01 for Agilent SureSelect,
p = 1.6*10-4 for Roche NimbleGen, two tails paired t test).
Overall, Roche NimbleGen technology showed a higher
level of duplicated reads than Agilent SureSelect for
both FF (p = 0.01, two tails paired t test) and FFPE
samples (p = 1.6*10-4, two tails paired t test) (Fig. 1a,
Additional file 2: Table S1).
Despite the higher number of PCR-duplicates in FFPE
samples, the mean target coverage, estimated without
duplicated reads, showed similar results for FF and FFPE
samples. Specifically, the mean values achieved in Agi-
lent libraries were 44.2× (range 40.7-48.4) and 44.5×
(range 41.0-47.8) for FF and FFPE libraries respectively,
whereas for Roche NimbleGen kit the mean values were
33.8× (range 27.7-44.9) and 31.9× (range 26.5-37.4) for
FF and FFPE libraries, respectively (Additional file 2:
Table S1). Overall, the total number of reads was gener-
ally lower for Agilent libraries. The higher mean target
coverage achieved in Agilent libraries was not surprising,
as the kit intended target region covers 50 Mb of the
genome, compared to the 64 Mb target region covered
by Roche NimbleGen kit. However, even taking into ac-
count the difference in the target region length, the
mean target coverage achieves a better performance in
Agilent kit with respect to the number of reads per sam-
ple. Moreover, when we considered the percentage of
target bases achieving at least a certain coverage thresh-
old, the Agilent SureSelect kit showed a better perform-
ance. In particular, on average, more than 90 % of
intended target region exhibited at least 10× coverage in
both FF and FFPE Agilent libraries compared with 88 %
(FF) and 85 % (FFPE) of target which had at least 10×
coverage in Roche NimbleGen libraries (Fig. 1b). Finally,
the percentage values of bases on target are higher in FF
than FFPE libraries in both exome platforms (p = 0.03
for Agilent SureSelect, p = 0.04 for Roche NimbleGen,
two tails paired t test), and show a better performance of
Agilent SureSelect kit over the Roche NimbleGen kit for
both FF (p = 1.1*10-4, two tails paired t test) and FFPE
samples (p = 1.5*10-4, two tails paired t test) (Fig. 1c,
Additional file 2: Table S1).
Variant detection and genotype comparison between FF
and FFPE samples
To assess the suitability of FFPE samples for WES ana-
lysis, we determined the total number of SNVs and In-
sertion/Deletions (InDels) in all FF-FFPE pairs. Then, we
determined the number of variants in common between
both sample types and unique to either FF or FFPE sam-
ple (Fig. 2, Additional file 2: Table S2). On average, both
capture system kits showed a percentage of shared SNVs
higher than 90 % (Fig.2a, Additional file 2: Table S2);
whereas the average percentage of common InDels
within each pair was lower than 80 % (Fig.2b, Additional
file 2: Table S2). This data might be probably due to the
GATK variant caller, which requires higher coverage to
accurately call InDels compared to SNVs, as suggested
by Wong et al. [36]. Moreover, we determined the geno-
type concordance rate (CR) and non-reference discord-
ance rate (NRDR) between each matched FF-FFPE pair
at different coverage thresholds, for both exome capture
systems. As shown in Additional file 2: Table S3a and in
Fig. 3a, for Agilent SureSelect kit the average CR across
all the five matched pairs was quite constant (≥97 %)
across all coverage thresholds. Similarly, NRDR reported
unvaried trend with a weak decrease from 6 % to 3 % at
increasing coverage cut-offs (Additional file 2: Table S3b,
Fig. 3b). For Roche NimbleGen kit, the average CR was
lower than Agilent SureSelect kit (p = 1.42*10-17,
ANOVA two-factor without replication), with a reduc-
tion from 95 % to 92 % at increasing coverage cut-offs
(Additional file 2: Table S3a, Fig. 3a); similarly, the aver-
age NRDR values resulted worse in Roche NimbleGen
libraries (p = 1.33*10-18, ANOVA two-factor without rep-
lication), with an increase at higher coverage cut-offs
(Additional file 2: Table S3b, Fig. 3b).
In order to determine if FFPE samples were signifi-
cantly enriched of FFPE artefacts (C > T and G > A sub-
stitutions), for both kits we computed CR and NRDR
between each matched FF-FFPE pair at increasing cover-
age thresholds for each transition type (Additional file 2:
Table S4). CR computed for either C > T or G > A substi-
tutions was not significantly different (p-value <0.01)
from the rate of the other transition types (A > G, T > C).
(See figure on previous page.)
Fig. 1 WES metrics comparison. Mean percentage ± SD (n = 5) of mapped, properly paired and duplicated reads obtained for each exome capture
technology in both FF and FFPE libraries (a). Mean percentage ± SD (n = 5) of target bases achieving a certain coverage value or higher for each library
type suggests that Roche kit tends to accumulate reads in low coverage regions (b). Mean percentage ± SD (n = 5) of on target bases for each library
type. On target bases are referred to the number of aligned bases that map either on or near a bait within a 100 bp interval (c)
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The only exception was C > T compared to T > C in
Agilent SureSelect kit at the highest coverage threshold
(Additional file 2: Table S4a). Similarly, NRDR values
computed for either C > T or G > A substitutions were
not significantly different (p-value <0.01) from other
transition types (A > G, T > C), although as coverage
threshold increases (≥30×), in both kits the NRDR
metric is able to spot significant differences due to cyto-
sine deamination (Additional file 2: Table S4b). In
Agilent SureSelect kit the NRDR values for C > T and
G > A were twice the values of other transitions at 50×
but still under 5 %.
Variant detection and genotype comparison between
exome capture systems
We systematically compared the ability of the two exome
capture systems to identify genomic variants. To this end,
we determined the percentage of SNVs and InDels de-
tected by both Agilent SureSelect and Roche NimbleGen
kits across either their own target regions of 50 Mb and
64 Mb respectively (Fig. 4 a, b), or the common target re-
gion of 42 Mb (Fig. 4 c, d), for each FF and FFPE sample.
When comparing the variant calling performance of the
two kits across their whole specific target regions, the
average percentage of common SNVs and InDels was ap-
proximately 48 % and 24 % respectively in both FF and
FFPE samples (Fig. 4 a, b; Additional file 2: Table S5). This
result was expected, since the two systems share almost
half of the total enrichment space (42 Mb over a total of
72 Mb). When we considered this specific shared region
for the comparison, the average percentages of common
SNVs and InDels were found to be 92.4 % (FF: 91.9 %;
FFPE: 93 %) and 68.9 % (FF: 69.7 %; FFPE: 68.1 %), re-
spectively (Fig. 4 c, d, Additional file 2: Table S5). Further-
more, for each FF and FFPE sample, we computed CR and
NRDR across the 42 Mb region shared between the two
platforms (Additional file 2: Table S6). The average
CR is ≥97 % and 98 % in FF and FFPE samples
a
b
Fig. 2 Variant calling comparison between FF and FFPE samples. The mean ± SD, computed across five matched FF-FFPE pairs, of the percentage
of SNVs (a) and InDels (b) common to both sample types (blue) and unique to either FF (red) or FFPE (green) samples is reported for both cap-
ture systems. They both show on average≥ 90 % of shared SNVs, and < 80 % of common InDels between FF and FFPE samples
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respectively, and it slightly decreases at coverage
thresholds ≥ 40× (Additional file 2: Table S6a); simi-
larly, NRDR is on average 5 % and 4 % in FF and
FFPE samples respectively, increasing at coverage cut-
offs ≥ 40× (Additional file 2: Table S6b).
Variant detection comparison between WES and
AmpliSeq Colon and Lung Cancer Panel
All samples included in the study were previously charac-
terized using the “Ion AmpliSeq Colon and Lung Cancer
Panel v.1” (Thermo Fisher Scientific) that screens targeted
regions of 22 lung cancer-related genes, and sequenced by
Ion Torrent PGM™ platform. In order to assess the
concordance between WES and target PCR-based re-
sequencing, we first examined the enrichment perform-
ance of the two WES kits. To do this we evaluated the
mean coverage achieved by both capturing systems within
the 90 PCR-captured regions contained in the 22 genes of
interest (Additional file 3: Table S7). Considering the
mean coverage across all the 90 regions, the Agilent
SureSelect kit was found to have a higher mean coverage
compared to the Roche NimbleGen (43.9×, range 4-145 vs
35.6× range 2-107), as already observed. Additionally, both
enrichment systems showed no relevant difference com-
paring FF and FFPE samples within each single region,
reporting a similar trend between the two sample types
(Agilent: 42.5× ± 7.8 FF vs 45.3× ± 9.1 FFPE; Roche: 34.5×
± 9.7 FF vs 37.2× ± 8.0 FFPE), with a slight but not-
significant increase of coverage in FFPE samples by both
technologies (Fig. 5 a, b). Despite the higher mean cover-
age achieved by Agilent system, its libraries showed a
lower uniformity across the amplicons, with a higher
number of regions with low read depth (20 amplicons
with coverage <20× vs 13 of Roche) or very high coverage
(10 amplicons with coverage >80× vs 2 of Roche) (Fig. 6).
It is worth to mention that both capture systems showed
a scarce coverage in TP53, one of the most frequently mu-
tated genes in cancer [37, 38], with only 3/8 amplicons




Fig. 3 Genotype concordance (CR) and non-reference discordance (NRDR) rates between matched FF-FFPE pairs computed at increasing coverage
thresholds. The mean ± SD across five matched FF-FFPE pairs of the CR % (a) or of the NRDR % (b) is reported at each coverage threshold for both Agi-
lent and Roche kit
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35-7578503; Roche NimbleGen: Chr17:7577489-7577636;
Chr17:7578160-7578320; Chr17:7579330-7579506) (Fig. 6,
Additional file 3: Table S7).
We further assessed the degree of variant calling con-
cordance between WES and the targeted re-sequencing
approach. Specifically, the VC plugin on Ion PGM™ data
identified a total of 64 genetic variants (50 in exons and
14 in exon-intron junction regions), reporting a 94 % of
concordance between FF and FFPE mutational profiles. Two
SNVs (NM_000455.4 (STK11): c.157G>C, p.Asp53His;
NM_000546.5 (TP53): c.476C >A, p.Ala159Asp) were only
identified in two FFPE samples (Additional file 3: Table
S8) suggesting an intra-tumor heterogeneity as commonly
described in lung cancer [39]. Although the average cover-
age obtained per sample by WES was only 30-40× com-
pared to more than 2000× achieved by the PCR-based kit,
both enrichment kits showed a good performance in the
exon variant call data, revealed by 88 % of concordance of
each kit with Ion data (44 out of 50 exon variants) (Fig. 7 a,
b, Additional file 3: Table S8). Additionally, the variant
frequency of shared variants was similar between Ion
PGM™ and WES data from both kits (Fig. 7a). None of the
exome capture systems reported any further variants in
the target regions analyzed by Colon and Lung Cancer
Panel. We observed that the 4 Ion PGM™ variants missed
by the GATK pipeline in both exome capture systems
(NM_005235.2 (ERBB4): c.2784 T > A, p.Glu928Asp;
NM_005228.3 (EGFR): c.2236_2250del, p.Glu746_Ala750del;
NM_000455.4 (STK11): c.157G>C, p.Asp53His;NM_000546.5
(TP53): c.476C>A, p.Ala159Asp), were called by Ion pipe-
line with a low frequency (4.2–16.6 %). However, these
variants were successfully confirmed by visual inspection
of alignments obtained from both exome kits, with a simi-
lar frequency reported by Ion PGM™ (range: 2–10 %). The
only exception was TP53 variant, that was missed by
Roche NimbleGen system due to an unsuccessful cover-
age (9× only). Roche failed to call two further variants
(NM_001127500.1 (MET): c.534C >T, p.(=); NM_000546.5
(TP53): c.380C >T, p.Ser127Phe) in two FFPE samples due
to unsuccessful coverage (2× and 3×, respectively). Similarly,
the Agilent SureSelect system missed a nonsynonymous
coding region in SMAD (NM_005359.5: c.1081C > A,
p.Arg361Ser) and one in-frame deletion in NM_005228.3
(EGFR): c.2236_2250del, p.Glu746_Ala750del, due to a
variant caller issue; however, the examination of the BAM
files by visual inspection confirmed the presence of both
a b
c d
Fig. 4 Variant calling comparison between Agilent SureSelect and Roche NimbleGen kit. Mean percentage ± SD of SNVs and InDels common to
both library prep kits (blue), and private to either Roche (red) or Agilent (green) kit in both FF and FFPE samples. The average percentage of
common SNVs (a) and InDels (b) was approximately 48 % (FF: 47.8 %; FFPE: 48.5 %) and 24 % (FF: 24 %; FFPE: 23.5 %) across the whole target
region specific for each kit. The average percentage of common SNVs (c) and InDels (d) was approximately 92 % (FF: 91.9 %; FFPE: 93 %) and
69 % (FF: 69.7 %; FFPE: 69.1 %) across the 42 Mb target region shared between the two kits
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a
b
Fig. 5 Coverage distribution across 90 PCR-capture amplicons between FF and FFPE samples. Coverage distribution across the 90 ‘AmpliSeq
Colon and Lung Cancer Panel’ regions displays a similar trend between the FF (blue) and FFPE (red) libraries in both Agilent SureSelect (a) and
Roche NimbleGen (b) libraries respectively, with a slightly better coverage in FFPE samples. Each amplicon is identified by a number as reported
in Additional file 3: TableS7
Bonfiglio et al. BMC Cancer  (2016) 16:692 Page 10 of 18
alternative alleles. Finally, when we considered the non-
exonic variants (intron/downstream/upstream regions),
the Agilent SureSelect enrichment kit showed a worse
performance, reporting no call among the 14 Ion variants
compared to 10/14 detected by the Roche NimbleGen
system (Fig. 7 c, d). However, the 14 calls involved only
two Single Nucleotide Polymorphism (SNPs), in EGFR
(NM_005228.3: c.1498 + 22A > T) (10/14) and ERBB4
(NM_005235.2: c.421 + 58A >G) (4/14), both excluded
from the Agilent design although the BAM file visual
inspection confirmed the EGFR variant. The Roche design
did not include ERBB4 position, thus explaining the failed
calls in Roche libraries, despite the ERBB4 SNP was
confirmed by BAM file visual inspection in four positive
libraries.
Coverage of cancer related genes
To further assess the WES potential in retrieving clinically
relevant genetic variants related to cancer phenotype, we
investigated the exon coverage of the most relevant
cancer-related genes. Specifically, we selected 623 genes
by matching the gene lists of 21 commercialized cancer-
specific panels (Additional file 4: Table S9). The coverage
distribution across all the coding exons of the selected
genes in each library was performed applying the GATK
DiagnoseTarget tool, according to the defined criteria. We
Fig. 6 Comparison of coverage distribution across 90 PCR-capture amplicons of both WES systems. The comparison shows a lower uniformity
across the amplicons in Agilent libraries, with a higher number of low read depth regions (20 amplicons with coverage <20× vs 14 of Roche) or
very high coverage (10 amplicons with coverage >80× vs 2 of Roche). Both whole exome capture systems showed a poor coverage in TP53 with
5/8 unsuccessfully covered amplicons (<20×) in each WES system. Coverage values were transformed in logarithmic scale
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found that 35.8 % of genes (223/623) showed all coding
exons successfully covered by both Agilent and Roche kits
(Fig. 8a). Conversely, 29.2 % (182/623) of the genes re-
ported at least one ‘critical’ region in both kits, and 16 out
of 182 genes had three or more low coverage regions in
both kits. The Roche kit reported further 106/623 genes
(17.0 %) with one or more critical regions, in addition to
the 182 genes shared with Agilent. Among them, for 4
genes (MYCN, PBX1, RUNX1T1, and SEPT9), one or
more exonic regions were excluded from the Roche target
design, although in only one RUNX1T1 exon a mutation
has been reported in the Catalogue of Somatic Mutation
in Cancer (COSMIC) database (data not shown) (http://
cancer.sanger.ac.uk/cosmic) [40, 41]. Further 75, 11, 13
and 2 genes out of 106 carried one, two, three and four in-




Fig. 7 Variant calling comparison between Ion PGM data and both WES systems. Variant calling comparison between Ion PGM data (blue) and
both Agilent SureSelect (green) and Roche NimbleGen (red) data in exon regions shows 88 % of concordance (44/50) in both WES capture
systems (a). Both systems failed to call 4 genetic variants (*) detected by Ion PGM platform at low frequencies (4-16 %). Further 4 variants were
missed as follows: 2 by Agilent (COSM6225, rs80338963) and 2 by Roche NimbleGen (COSM40942, rs35775721). Horizontal axis reports the
genetic variants (Additional file 3: Table S8a) ordered from lowest to highest frequency (vertical axis) as assessed by Ion PGM platform. Variant
coverage displays a quite similar trend between Agilent (green) and Roche NimbleGen (red) libraries, and is far lower than Ion PGM platform
(blue) (b). Two Roche libraries report a low coverage in the uncalled variants (COSM40942, rs35775721). Vertical axis displays the variant coverage
in logarithmic scale. Variant calling comparison between Ion PGM data (blue) and both Agilent (green) and Roche NimbleGen (red) data in non-
exon regions shows a poor performance of both WES technologies (c). Both WES systems failed to call the rs839541 (*) SNP in ERBB4 gene,
whereas rs1558544 SNP in EGFR was missed by all 10 Agilent libraries. Vertical axis reports the frequency of the genetic variants. Variant coverage
comparison between Ion PGM data (blue) and both Agilent (green) and Roche NimbleGen (red) data in non-exon (intron/downstream/upstream)
regions reports a low coverage in both exome capture kits (d); rs839541 SNP was completely uncovered in Agilent libraries. Vertical axis displays
coverage values in logarithmic scale




Fig. 8 Coverage distribution across all the coding exons of 623 cancer-related genes in both WES platforms. Distribution summary of 623
cancer-related genes according to their coverage performance achieved in the two tested WES systems (a). Specifically, 36 % of the
genes (red) were completely well covered by both Agilent and Roche kits; 29 % (blue) had at least one ‘critical’ region in both kits; 18 %
were completely well covered by Roche NimbleGen kit, but had one or more ‘critical’ region in Agilent SureSelect kit; finally, 17 % of the
genes were completely well covered by Agilent SureSelect kit, but had one or more problematic region in Roche NimbleGen kit. Distribution summary
of cancer-related genes having one (73 %), two (12 %) or more (15 %) critical regions in NimbleGen Roche kit, but completely well-covered in Agilent
SureSelect kit (b). Distribution summary of cancer-related genes having one (66 %), two (25 %) or more (9 %) critical regions in Agilent SureSelect kit,
but completely well-covered in Roche NimbleGen kit (c)
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(Fig. 8b). Moreover, eight out of 20 exons were flagged as
‘critical’ in one MST1R gene. Similarly, 112/623 genes
(18.0 %) carried one or more ‘critical’ exonic regions in
Agilent libraries only (Fig. 8a).
Agilent design did not include one or more exons con-
taining at least one cancer-linked mutation listed in
COSMIC for 4 out of 112 genes (BRCA1, KMT2C,
H3F3A, and SSX1) (data not shown). Furthermore, 73,
26, 4 and 3 genes out of 112 carried, respectively, one,
two, three and four low coverage regions in Agilent Sur-
eSelect kit; further 2 genes had a higher number of
exons with low coverage (YES1 and MUC16 carrying 5/
11 and 15/84 exonic regions with low read depth, re-
spectively) (Fig. 8c).
We also evaluated the coverage performance of the
two kits with respect to the sub-group of the 623
cancer-related genes which were prioritized according to
their presence in four databases: Cancer Drivers Data-
base 2014.12 [42], Gene-Drug Knowledge Database v.9.0
[43], EXaCT-1 [44] and TARGET v.3 [23]. Among the
182 genes with at least one critical region in both WES
kits (174 with insufficient coverage and 8 with poor
mapping quality), 27 (14.8 %) were reported in at least 3
databases, and 8/27 (ALK, BRAF, CDH1, ERBB2,
NOTCH1, PTEN, RB1, and TP53) were also shared in at
least 10 re-sequencing panels (Additional file 4: Table
S9). Furthermore, 4/27 genes (BRAF, MAP2K4, NF1, and
RB1) performed worse in Agilent than in Roche kit, i.e.
they carry only one ‘critical’ region in Roche libraries
compared to four or more problematic regions in Agi-
lent samples (Additional file 4: Table S9). Conversely,
Roche kit showed a worse performance in 5/27 genes
carrying three (ALK and DNMT3A), five (TP53), six
(JAK3) and seven (ERCC2) critical exons compared to
only one critical exon in Agilent libraries (Additional file
4: Table S9). When we focused on the genes with the
worst performance in Roche libraries only, we retrieved
a list of 25 genes shared in at least 3 databases and
among them we found 5 genes having more than three
low coverage regions (BAP1, FLCN, NTRK1, SMARCA4,
and WT1) (Additional file 4: Table S9). On the contrary,
among the 22 potentially critical genes present in at least
3 databases and incompletely covered in Agilent librar-
ies, only two (CREBBP and NPM1) reported several re-
gions with low coverage (Additional file 4: Table S9).
Finally, in order to better assess the translational po-
tential of WES data, we also investigated if the presence
of low coverage regions within 74 genes previously pri-
oritized (27 in both platforms, 25 in Roche, and 22 in
Agilent) could be critical for the occurrence of clinically
actionable mutations [43] in those regions. The intersec-
tion of data identified a total of 12 mutations linked to
therapeutic actions (Additional file 5: Table S10) within
5 low coverage exons in 5 genes (ALK, JAK3, AR,
FGFR2, and GNAQ). The mutations within ALK, AR
and GNAQ critical intervals had not uniform coverage
across the libraries (the coverage depth at all mutation
positions reached values ≤10× in only some libraries).
This suggested that the performance of the interval
could be library-dependent and not related to a low per-
formance of the bait. In contrast, four mutations
(A572V and A573V in JAK3; V565I and E566G in
FGFR2) achieved an extremely low read depth (<8×) in
almost all Agilent libraries. Interestingly, in additional
four Agilent libraries sequenced at high read depth
(mean coverage >100×) in our lab, the variant coverage
was similarly unsuitable (data not shown), leading to
hypothesize a low performance of the specific capturing
baits.
Discussion
WES applied to FFPE samples in the context of preci-
sion medicine and clinical cancer care has been recently
described [23, 44] showing the suitability of gDNA ex-
tracted from FFPE specimens for library preparation and
sequencing [22–28]. However, it is well known that ex-
tended formalin fixation could result in highly degraded
gDNA [45], possibly unsuitable for downstream applica-
tions such as sequencing. Power and limitations of dif-
ferent enrichment platforms should be benchmarked,
especially on critical samples such as FFPE specimens, if
intended use of WES is in clinical context.
Here we report a comparison study between two in-
solution capture platforms, Agilent SureSelect XT v.5
and Roche NimbleGen v.3, analyzing FF and matched
FFPE gDNA samples extracted from lung ADC tissues
(Additional file 1: Fig. S2). Low amount of degraded
gDNA from FFPE samples (300 ng) was not found to be
a limiting factor. As WES is still moderately expensive, a
QC step on FFPE gDNA should be mandatory, and dif-
ferent methods have been proposed [25, 26]. We evalu-
ated the degradation status of FFPE gDNA with two
different methods (PCR-based assay and automated gel-
based electrophoresis system) which provided similar in-
formation about the FFPE degradation status; FFPE
gDNA fragmented up to 70 % could be successfully se-
quenced. In agreement with our previous study, PCR
multiplex assay was a predictor for the success of PCR-
based capture re-sequencing [46]; furthermore, a recent
application note by Agilent showed similar results in a
pilot study on 197 FFPE gDNA, setting a QC cut-off ≥ 3
DIN to proceed to downstream workflow [47]. PCR-
based assays have the advantage to outline suitability of
FFPE gDNA to amplify specific genomic region sizes ac-
cording to the library dimension. On the other hand,
Agilent 2200 TapeStation system, which reports frag-
mentation pattern over the whole genome, is optimal in
genome wide studies, it is a time-effective alternative to
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a PCR-based assay and it allows to save gDNA for fur-
ther downstream applications (~5 ng of gDNA input vs
30-100 ng for the multiplex-PCR QC assay).
Analysis of sequencing metrics showed that Agilent
SureSelect XT kit achieved a higher ratio of on-target
bases, similarly to Shigemizu et al. [21]. We also found a
statistically significant increase of duplicated reads in
FFPE samples compared to matched FF samples in both
kits. This result is possibly a consequence of lower
library complexity, which usually occurs when the
amount of gDNA is very low or highly degraded, such as
FFPE gDNA [24, 36]. Despite the input FFPE gDNA was
the same, Roche NimbleGen resulted in even higher
sequence duplication rate. Roche NimbleGen libraries
reported lower values of mean target coverage; this
difference was mainly due to the larger size of its target
region (64 Mb vs 50 Mb). Both enrichment systems
reported high concordance of variant calling between
matched FF and FFPE samples while concordance on
InDel calls in matched FF-FFPE pairs was lower, prob-
ably as result of a low mean coverage [36]. Genotype CR
of shared SNVs between the platforms on the common
42 Mb target region was nearly 100 % and it was found
high at different coverage thresholds for both platforms,
with Roche system revealing slightly decreasing values at
higher coverages. We speculate that this behaviour, mir-
rored by an increasing NRDR, might be related to the
intra-pair heterogeneity highlighted when the percentage
of target bases covered at least a certain coverage thresh-
old (i.e. ≥ 30×) was taken into account.
DNA artefacts that arise from formalin crosslinking in-
crease false positive calls; treatment with uracil-DNA
glycosylase (UDG), included in some gDNA isolation
procedures, such as GeneRead DNA FFPE kit (Qiagen),
allows the removal of cytosine deamination artefacts,
minimizing the risk of false SNP calls [48]. We hence in-
vestigated the prevalence of known FFPE artefacts (C >
T and G > A substitutions) in FFPE samples treated with
UDG. In general, CR and NRDR values computed for
C > T and G > A substitutions were found in line with
other transition rates. FFPE artefacts are estimated to
happen at a rate ~10 %, a level similar to sub-clonal mu-
tations in heterogeneous cancer samples, and can be
highlighted with high coverage data [48]. In line with
this finding, we found that spurious calls due to cytosine
deamination can only be identified at the highest cover-
ages, although absolute rates remain low when UDG
treatment is applied. Despite the encouraging results
obtained with gDNA extracted from FFPE samples, we
cannot exclude that the library preparation starting from
lower quality input gDNA samples might be more chal-
lenging [24].
By hypothesizing the use of WES data in a clinical
context, we also evaluated the performance in variant
detection of both the enrichment systems over 22 lung
cancer-related genes (90 amplicons) included in the
AmpliSeq Colon and Lung Cancer Panel v.1, using
sequencing data obtained from Ion Torrent PGM™ plat-
form as positive control. We observed that Agilent li-
braries reported lower read depth uniformity across the
90 amplicons, despite the higher mean coverage over the
whole exome target region. The same response has been
also reported as a platform bias in previous versions of
the kit [15, 49]. Our comparison analysis displayed that
nearly 90 % of variants detected by the Ion Torrent plat-
form were correctly called with a similar frequency in
both platforms, without false positives, irrespective of
the type of input gDNA. This good concordance was
achieved despite the uneven coverages on the two se-
quencing systems (~30×-40× on HiSeq vs ~2000× on
Ion Torrent platform). Both enrichment systems showed
their potential of retrieving clinically actionable single
nucleotide substitutions, e.g. COSM6224 linked to the
activity of EGFR inhibitors [50, 51], except for those
spanning exon-intron junctions, due to missing probes
in their target designs. We finally challenged the two en-
richment platforms in the characterization of 623
cancer-related genes selected from 21 commercial gene
panels. While both kit designs covered almost all the ex-
onic regions of those genes, with nearly half of them effi-
ciently captured, we were able to describe few genes
marked by one or more low coverage exons that could
be critical for therapeutic targeting. Overall, the ability
of the two kits to efficiently cover cancer-related genes
in both FF and FFPE samples is satisfactory and compar-
able between the two systems. We speculate that WES
approach, which allows the analysis of all cancer genes
under investigation, could be an efficient alternative op-
tion compared to target re-sequencing panels with the
major advantage it allows to describe the mutational
landscapes linked to tumor progression, novel drug
resistance-associated mutations and even assist thera-
peutic choice due to the rapid rate of novel targeted
therapies development [44].
Conclusions
Our data substantiate the feasibility of generating high-
quality libraries and sequencing data from relatively low
input of highly fragmented FFPE gDNA, without signifi-
cant differences between the two tested platforms.
We also demonstrate that each WES platform is able
to correctly detect most of the SNVs detected by a PCR
capture re-sequencing, without introducing false nega-
tive results. Furthermore, both WES capture systems
efficiently cover almost all exons of the most cancer-
relevant genes.
Therefore, our study demonstrates that FFPE samples
may replace the frozen tissues in a WES workflow,
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although a QC step of FFPE degradation status should
be integrated as a decision criterion to proceed for the
sequencing.
Researchers should keep in mind that the WES de-
signs continuously evolve and both technologies recently
released new versions namely Human All Exon v.6
(Agilent Technologies) and SeqCap EZ MedExome
Kit (Roche NimbleGen) that have been optimized in
design with an improvement of the disease-linked
variant detection.
In conclusion, our analysis suggests that the WES ap-
proach could be extended to a translational research
context as well as to the clinic (e.g. to study rare malig-
nancies), where the simultaneous analysis of the whole
coding region may help in the detection of cancer-linked
variants.
Additional files
Additional file 1: Figure S1 and Figure S2. Figure S1. DNA quality
control. TapeStation profiles of gDNA isolated from FF and matching
FFPE block tumor tissues from 5 lung ADC patients. In each profile, the
DIN, indicative of gDNA degradation status, is also displayed (numerical
assessment ranges from 10 for undamaged gDNA, to 1 for highly
fragmented gDNA) (a). The Table reports the gDNA concentration (ng/ul)
assessed by NanoDrop, Qubit, and TapeStation, and purity (260/280 and
260/230) (b). Additionally, AYR and DIN parameters, indicative of FFPE
gDNA fragmentation status, evaluated by a multiple PCR assay and
TapeStation respectively, are reported. Image of agarose gel 1 % shows
the gDNA smears indicative of the different degradation status of FF and
FFPE gDNAs (c). Figure S2. The workflow illustrates samples processing
and WES data analysis for both exome enrichment platforms.
(PDF 187 kb)
Additional file 2: Table S1, Table S2, Table S3, Table S4, Table S5,
and Table S6. Table S1. Sequencing metrics for libraries prepared with
both Agilent SureSelect XT v.5 and Roche NimbleGen v.3.0 kits starting
from five matched FF and FFPE tumor samples. Table S2. Variant
detection comparison between matched FF-FFPE pairs. For each matched
FF-FFPE pair, the number and the percentage of both SNVs and InDels
common to both sample types, and unique to either FF or FFPE sample are
reported. Table S3. Genotype CR and NRDR between matched FF-FFPE
pairs at increasing coverage thresholds. For each matched FF-FFPE pair, the
genotype CR was computed as the ratio between the sum of concordant
genotypes and the sum of all genotypes called at genomic positions
covered at least a certain coverage threshold (from 1 to 50×) in both
samples (a). For each matched FF-FFPE pair, the NRDR was computed as
the ratio between the sum of non-concordant genotypes and the sum of
all non-reference genotypes called at genomic positions covered at least a
certain coverage threshold (from 1 to 50×) in both samples (b). Table S4.
Genotype CR and NRDR between matched FF-FFPE pairs computed for
each transition type at increasing coverage thresholds. For each matched
FF-FFPE pair, the genotype CR for each transition type was computed as the
ratio between the sum of concordant genotypes and the sum of all
genotypes called at genomic positions covered at least a certain coverage
threshold (from 1 to 50×) in both samples; p-values for two-tail t-test for
each comparison between two transition types are reported at the bottom
of the table (a). For each matched FF-FFPE pair, the NRDR for each transition
type was computed as the ratio between the sum of non-concordant
genotypes and the sum of all non-reference genotypes called at genomic
positions covered at least a certain coverage threshold (from 1 to 50×) in
both samples; p-values for two-tail t-test for each comparison between two
transition types are reported at the bottom of the table (b). Table S5.
Variant detection comparison between exome libraries prepared with both
Agilent SureSelect and Roche NimbleGen kit. The table reports the total
number and the percentage of SNVs and InDels common to both library
prep types for each sample, and unique to either Agilent SureSelect and
Roche NimbleGen kit. The comparison was performed considering both the
whole kit-specific target region and the 42 Mb of common target region.
Table S6. Genotype CR and NRDR rates within the shared 42 Mb target
region between Agilent SureSelect and Roche NimbleGen at increasing
coverage thresholds. For each sample, the genotype CR was computed as
the ratio between the sum of concordant genotypes and the sum of all
genotypes called at genomic positions covered at least a certain coverage
threshold (from 1 to 50×) in both Agilent SureSelect and Roche NimbleGen
libraries (a). For each sample, the NRDR was computed as the ratio between
the sum of non-concordant genotypes and the sum of all non-reference
genotypes called at genomic positions covered at least a certain coverage
threshold (from 1 to 50×) in both in both Agilent SureSelect and Roche
NimbleGen libraries (b). (XLSX 54 kb)
Additional file 3: Table S7 and Table S8. Table S7. Mean coverage
achieved by Agilent SureSelect and Roche NimbleGen libraries within 90
PCR-capture amplicons. Mean coverage ± SD within 90 regions amplified
by AmpliSeq Colon and Lung Cancer Panel v.1 (Thermo Fisher Scientific)
from ‘FF’, ‘FFPE’ and ‘FF plus FFPE’ samples achieved by Agilent SureSelect
and Roche NimbleGen libraries respectively. In each column, the mean
coverage values are reported for each amplicon, and the heat map was
created using two-color scale (lowest value is represented by dark blue
and highest value by dark red). Table S8. Variant calling comparison
between the two WES systems (Agilent SureSelect and Roche NimbleGen)
and the AmpliSeq Colon and Lung Cancer Panel. List of FFPE and matched
FF samples genetic variants called by VC v.4.2 plugin on Ion PGMTM data
and GATK pipeline in both exome capture systems. All variants are annotated
with gene ID, locus, reference sequence, variant allele according to the
hg19 Reference Genome. The red bars show the variant allele frequency (%)
detected by VC on Ion pipeline and GATK on both Agilent SureSelect and
Roche NimbleGen WES (0* means variant not called but found by IGV visual
inspection of BAM files). All variants are annotated for COSMIC or dbSNP
(rs number) together with the codons involved and the amino acid change
(AA). The 'Effect' column reports if the variant is in a coding region, discerning
between nonsynonymous, synonymous and non-sense, or in an intron,
downstream the gene or in a splicing region. The last four columns of the
table reports the Minor Allele Frequency (MAF) reported in the 1000
Genomes Project, the prediction effect on the protein based on SIFT and
Polyphen algorithms and the conservation score namely GERP. For SIFT
prediction, the higher the number, the lower is the effect, whereas for
Polyphen prediction is the opposite. Thus, a higher score for GERP
indicates a higher conservation of the gene across 34 mammalian
species. Abbreviation: - not available data. (XLSX 44 kb)
Additional file 4: Table S9. Coverage distribution across all the coding
exons of the 623 cancer related genes in each library. For each gene, the
table reports the number of coding RefSeq exons downloaded from
UCSC, their presence within 21 commercial re-sequencing cancer panels
and further four cancer genes databases. The coverage distribution across
all coding exons was performed using the GATK DiagnoseTarget tool. For
each WES capture platform we reported: the number of ‘critical’ exons
(average depth of coverage < 10× for at least 20 % of the length of the
interval and with insufficient median depth across all FF and FFPE libraries),
the number of exon regions missed by the kit target design file, and the %
of passed exons (average depth of coverage≥ 10× for at least 20 % of the
length of the interval). (XLSX 120 kb)
Additional file 5: Table S10. Clinically actionable mutations within low
coverage exons of database-prioritized cancer related genes. For each
selected genomic interval the table reports the mean coverage and SD
values in both Agilent SureSelect and Roche NimbleGen libraries, and the
list of clinically actionable mutations belonging to that interval, retrieved
from Gene-Drug Knowledge Database v9.0 [43]. (XLSX 13 kb)
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